Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million

283
16
Favorite

Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million

Barron's2022-10-18

The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

283

Report

Comment（16）

ArcherWG
·2022-10-19
Noted
Reply
1
Report
YJ Lee
·2022-10-19
Ok
Reply
3
Report
Fold Replies
- sleepycat:
  stonks
  2022-10-19
  Reply
  Report
andrew123
·2022-10-19
Lile
Reply
6
Report
Fold Replies
- Myname:
  Ok
  2022-10-19
  Reply
  Report
ArcticFox88
·2022-10-19
Like
Reply
4
Report
Fold Replies
- ArcticFox88:
  Ok
  2022-10-19
  Reply
  Report
hanyoung
·2022-10-19
👍
Reply
3
Report
Fold Replies
- Andersonkana:
  goog
  2022-10-27
  Reply
  Report
- Andersonkana:
  good
  2022-10-27
  Reply
  Report
- Mib1515:
  K
  2022-10-19
  Reply
  Report
KCtan1688
·2022-10-19
Like
Reply
4
Report
Fold Replies
- KCtan1688:
  Lole
  2022-10-19
  Reply
  Report
DarrenTayCW
·2022-10-19
great
Reply
1
Report
phantom74
·2022-10-19
like
Reply
1
Report
AngelaChan
·2022-10-19
Interesting
Reply
2
Report
Fold Replies
- AngelaChan:
  what's next?
  2022-10-19
  Reply
  Report
Seah CL
·2022-10-19
K
Reply
1
Report
ML808
·2022-10-19
Cool
Reply
1
Report
Fold Replies
- ML808:
  yes
  2022-10-19
  Reply
  Report
SMLim
·2022-10-19
Ok
Reply
1
Report
Fold Replies
- SMLim:
  [Miser]
  2022-10-19
  Reply
  Report
yyhwin12345
·2022-10-18
Hi
Reply
1
Report
chrng
·2022-10-18
[Anger] [Anger] [Anger]
Reply
2
Report
kwk
·2022-10-18
Like
Reply
4
Report
Fold Replies
- Stephanie712:
  Ok
  2022-10-18
  Reply
  Report
lyj1999
·2022-10-18
Nice
Reply
3
Report
Fold Replies
- Benedict_cyh:
  F
  2022-10-19
  Reply
  Report
- yyhwin12345:
  Lhi
  2022-10-18
  Reply
  Report
- SiniS:
  👍🏻
  2022-10-18
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1136877041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-18 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136877041","market":"us","top_or_hot":-1,"title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","media":"Barron's","content":"<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Source Link</a>\n\n</div>\n","source":"lsy1610680873436","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","article_id":"1136877041","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","pubTimestamp":1666103219,"sourceInfo":{"source_id":"lsy1610680873436","name":"Barron's"},"weMediaInfo":null,"summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"translate_title":"礼来公司以6.1亿美元收购基因治疗公司，Akouos股价飙升85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKUS":0.9,"LLY":0.9},"content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9983046071,"gmtCreate":1666133116194,"gmtModify":1676537709246,"author":{"id":"3581837121803380","authorId":"3581837121803380","name":"ArcherWG","avatar":"https://community-static.tradeup.com/news/38e40c44fababa6849ceb15dfe8931a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581837121803380","authorIdStr":"3581837121803380"},"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983046071","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9983040209,"gmtCreate":1666132570602,"gmtModify":1676537709128,"author":{"id":"4108816210230400","authorId":"4108816210230400","name":"YJ Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4108816210230400","authorIdStr":"4108816210230400"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983040209","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104404705,"gmtCreate":1666135344501,"gmtModify":1666135348398,"authorId":3576547960360401,"author":{"id":3576547960360401,"idStr":"3576547960360401","authorId":3576547960360401,"name":"sleepycat","avatar":"https://static.tigerbbs.com/5b377a1c5c1cb9846ec43d7fe2be8097","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983040209,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">stonks</span>","text":"<span class=\"s1\">stonks</span>","html":"<span class=\"s1\">stonks</span>"}],"langContent":"EN"},{"id":9983054871,"gmtCreate":1666132354093,"gmtModify":1676537709073,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f2a1eaba26272212d42018e60e78b422","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Lile","listText":"Lile","text":"Lile","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983054871","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104404030,"gmtCreate":1666133977424,"gmtModify":1666133981116,"authorId":3575455489344050,"author":{"id":3575455489344050,"idStr":"3575455489344050","authorId":3575455489344050,"name":"Myname","avatar":"https://static.tigerbbs.com/3fff4aa421deeb7a8d801ab27a14a82f","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983054871,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9983053014,"gmtCreate":1666131674138,"gmtModify":1676537708897,"author":{"id":"3581739666390904","authorId":"3581739666390904","name":"ArcticFox88","avatar":"https://static.tigerbbs.com/cb1f244ecf651567e5baa7863d330262","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581739666390904","authorIdStr":"3581739666390904"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983053014","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104403125,"gmtCreate":1666131680873,"gmtModify":1666131684142,"authorId":3581739666390904,"author":{"id":3581739666390904,"idStr":"3581739666390904","authorId":3581739666390904,"name":"ArcticFox88","avatar":"https://static.tigerbbs.com/cb1f244ecf651567e5baa7863d330262","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983053014,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9983050413,"gmtCreate":1666131538932,"gmtModify":1676537708866,"author":{"id":"3582866489463259","authorId":"3582866489463259","name":"hanyoung","avatar":"https://static.tigerbbs.com/3780c45000f0a7a6551c6935a8869cf5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582866489463259","authorIdStr":"3582866489463259"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9983050413","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104539081,"gmtCreate":1666883515829,"gmtModify":1666883519121,"authorId":4088599389256890,"author":{"id":4088599389256890,"idStr":"4088599389256890","authorId":4088599389256890,"name":"Andersonkana","avatar":"https://static.tigerbbs.com/21e08c99709245ba5acdcf7245d9c40f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983050413,"type":1,"supId":0,"prevId":0,"content":"<u>goog</u>","text":"<u>goog</u>","html":"<u>goog</u>"},{"id":104539076,"gmtCreate":1666883501102,"gmtModify":1666883504619,"authorId":4088599389256890,"author":{"id":4088599389256890,"idStr":"4088599389256890","authorId":4088599389256890,"name":"Andersonkana","avatar":"https://static.tigerbbs.com/21e08c99709245ba5acdcf7245d9c40f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983050413,"type":1,"supId":0,"prevId":0,"content":"<u>good</u>","text":"<u>good</u>","html":"<u>good</u>"},{"id":104409507,"gmtCreate":1666145914773,"gmtModify":1666145918526,"authorId":3579210010472476,"author":{"id":3579210010472476,"idStr":"3579210010472476","authorId":3579210010472476,"name":"Mib1515","avatar":"https://static.tigerbbs.com/c0b85730abdbda4c69ac70cb9d1f58cb","vip":1,"currentWearingBadge":{"badgeId":"4e86300037264823b9bb00ff44fc0f19-6","templateUuid":"4e86300037264823b9bb00ff44fc0f19","name":"Live trading challenger","description":"for 12 months","bigImgUrl":"https://community-static.tradeup.com/news/b76669c276447115bf9cde881b0cba68","smallImgUrl":"https://community-static.tradeup.com/news/6d5ffd25685d045ade4bb948ef8fd5c3","grayImgUrl":"https://community-static.tradeup.com/news/076cd4597f6ea22aabdd4f6a12b2c293","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5600},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983050413,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">K</span>","text":"<span class=\"s1\">K</span>","html":"<span class=\"s1\">K</span>"}],"langContent":"EN"},{"id":9983022084,"gmtCreate":1666130763348,"gmtModify":1676537708733,"author":{"id":"3572830110372716","authorId":"3572830110372716","name":"KCtan1688","avatar":"https://static.tigerbbs.com/eb264e77c49fffb1d26a89a47dbc0250","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572830110372716","authorIdStr":"3572830110372716"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983022084","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104402876,"gmtCreate":1666130770457,"gmtModify":1666130770457,"authorId":3572830110372716,"author":{"id":3572830110372716,"idStr":"3572830110372716","authorId":3572830110372716,"name":"KCtan1688","avatar":"https://static.tigerbbs.com/eb264e77c49fffb1d26a89a47dbc0250","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983022084,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Lole</span>","text":"<span class=\"s1\">Lole</span>","html":"<span class=\"s1\">Lole</span>"}],"langContent":"EN"},{"id":9983026595,"gmtCreate":1666130623817,"gmtModify":1676537708726,"author":{"id":"4095157923406380","authorId":"4095157923406380","name":"DarrenTayCW","avatar":"https://community-static.tradeup.com/news/fd3e65152635880712a6be051f621efa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095157923406380","authorIdStr":"4095157923406380"},"htmlText":"great","listText":"great","text":"great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983026595","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9983026897,"gmtCreate":1666130591619,"gmtModify":1676537708719,"author":{"id":"3570342809089528","authorId":"3570342809089528","name":"phantom74","avatar":"https://static.tigerbbs.com/c87ef2af41b8696be86cceafb5b5723d","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":0,"idStr":"3570342809089528","authorIdStr":"3570342809089528"},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983026897","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9983021709,"gmtCreate":1666130440101,"gmtModify":1676537708680,"author":{"id":"3581927959461394","authorId":"3581927959461394","name":"AngelaChan","avatar":"https://static.tigerbbs.com/89cd9fc4748e9cc19bd2df211f8ced9c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581927959461394","authorIdStr":"3581927959461394"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983021709","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104402784,"gmtCreate":1666130447304,"gmtModify":1666130451402,"authorId":3581927959461394,"author":{"id":3581927959461394,"idStr":"3581927959461394","authorId":3581927959461394,"name":"AngelaChan","avatar":"https://static.tigerbbs.com/89cd9fc4748e9cc19bd2df211f8ced9c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983021709,"type":1,"supId":0,"prevId":0,"content":"what's next?","text":"what's next?","html":"what's next?"}],"langContent":"EN"},{"id":9983021082,"gmtCreate":1666130281647,"gmtModify":1676537708656,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4102135564535180","authorIdStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983021082","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9983061589,"gmtCreate":1666127279041,"gmtModify":1676537708242,"author":{"id":"3582359360248748","authorId":"3582359360248748","name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3582359360248748","authorIdStr":"3582359360248748"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983061589","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104402214,"gmtCreate":1666127291115,"gmtModify":1666127294495,"authorId":3582359360248748,"author":{"id":3582359360248748,"idStr":"3582359360248748","authorId":3582359360248748,"name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983061589,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"},{"id":9983082307,"gmtCreate":1666114725109,"gmtModify":1676537708015,"author":{"id":"3586259427226842","authorId":"3586259427226842","name":"SMLim","avatar":"https://static.tigerbbs.com/b84ccf92cfb9ec3d527d12880bb472db","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586259427226842","authorIdStr":"3586259427226842"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983082307","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104401944,"gmtCreate":1666114740785,"gmtModify":1666114743966,"authorId":3586259427226842,"author":{"id":3586259427226842,"idStr":"3586259427226842","authorId":3586259427226842,"name":"SMLim","avatar":"https://static.tigerbbs.com/b84ccf92cfb9ec3d527d12880bb472db","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.05","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983082307,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">[Miser]</span>","text":"<span class=\"s1\">[Miser]</span>","html":"<span class=\"s1\">[Miser]</span>"}],"langContent":"EN"},{"id":9983033026,"gmtCreate":1666105835965,"gmtModify":1676537707011,"author":{"id":"3586228965364851","authorId":"3586228965364851","name":"yyhwin12345","avatar":"https://static.tigerbbs.com/f73f48f7dbf02904c9a179fb59cc138d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586228965364851","authorIdStr":"3586228965364851"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983033026","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9983095664,"gmtCreate":1666104785459,"gmtModify":1676537706866,"author":{"id":"3582062985733851","authorId":"3582062985733851","name":"chrng","avatar":"https://static.tigerbbs.com/89025d5e5363abd160c4ecc4d3a620b6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3582062985733851","authorIdStr":"3582062985733851"},"htmlText":"[Anger]&nbsp;[Anger]&nbsp;[Anger]&nbsp;","listText":"[Anger]&nbsp;[Anger]&nbsp;[Anger]&nbsp;","text":"[Anger] [Anger] [Anger]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9983095664","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9983095844,"gmtCreate":1666104774188,"gmtModify":1676537706866,"author":{"id":"3581666905348968","authorId":"3581666905348968","name":"kwk","avatar":"https://static.tigerbbs.com/2e8a435e0085881deaf4e2435fa579d3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581666905348968","authorIdStr":"3581666905348968"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9983095844","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104400629,"gmtCreate":1666104954161,"gmtModify":1666104957981,"authorId":3582030171524236,"author":{"id":3582030171524236,"idStr":"3582030171524236","authorId":3582030171524236,"name":"Stephanie712","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983095844,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9983007338,"gmtCreate":1666103451825,"gmtModify":1676537706576,"author":{"id":"3583137839879179","authorId":"3583137839879179","name":"lyj1999","avatar":"https://static.tigerbbs.com/5d7368738bf169cbe1003cad31acb204","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583137839879179","authorIdStr":"3583137839879179"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9983007338","repostId":1136877041,"repostType":4,"repost":{"id":"1136877041","kind":"news","pubTimestamp":1666103219,"share":"https://ttm.financial/m/news/1136877041?lang=&edition=fundamental","pubTime":"2022-10-18 22:26","market":"us","language":"en","title":"Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136877041","media":"Barron's","summary":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos fo","content":"<html><head></head><body><p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.</p><p>Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.</p><p><img src=\"https://static.tigerbbs.com/f73c1c1ae1e8f649586c2ccb6e21bb81\" tg-width=\"828\" tg-height=\"846\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/bed33aec19b9b78d25a51676852d47e7\" tg-width=\"830\" tg-height=\"828\" referrerpolicy=\"no-referrer\"/></p><p>The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.</p><p>“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.</p><p>Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.</p><p>Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.</p><p>The transaction is expected to close in the fourth quarter of 2022.</p></body></html>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkouos Stock Soars 85% as Eli Lilly Buys Genetic Therapies Company for $610 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","AKUS":"Akouos, Inc."},"source_url":"https://www.marketwatch.com/articles/akouos-stock-soars-eli-lilly-deal-51666098346?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136877041","content_text":"The pharmaceutical giant Eli Lilly announced that it will buy the genetic medicine company Akouos focused on hearing improvement, for up to $610 million.Shares of Akouos soared 85% in morning trading Tuesday to $13, while Lilly’s stock slipped 0.22%.The merger of these two companies is meant to help them accelerate gene therapies that will help improve hearing for patients, according to a joint news release.“We believe that with Lilly’s resources, global reach, and growing capabilities in gene therapy, we can help Akouos fulfill their mission of making healthy hearing available to all,” Andrew Adams, co-director at the Lilly Institute for Genetic Medicine, said in the news release.Lilly (ticker: LLY) will commence a tender offer to acquire all outstanding shares of  Akouos (AKUS) for a purchase price of $12.50 per share in cash, which equals around $487 million. The size of the deal could grow to about $610 million, or bump it up an extra $3-a-share to $15.50 if certain goals are hit linked to drug trials.Such contingent value rights will be paid based on the treatments for hearing loss hitting certain milestones throughout the next few years and gaining regulatory approval by the Food and Drug Administration by or before Dec. 31 of 2026.The transaction is expected to close in the fourth quarter of 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104401511,"gmtCreate":1666109146146,"gmtModify":1666109149781,"authorId":3581667328055955,"author":{"id":3581667328055955,"idStr":"3581667328055955","authorId":3581667328055955,"name":"Benedict_cyh","avatar":"https://static.tigerbbs.com/216a5cf2e56f81472309860a063b75a6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983007338,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">F</span>","text":"<span class=\"s1\">F</span>","html":"<span class=\"s1\">F</span>"},{"id":104400803,"gmtCreate":1666105850622,"gmtModify":1666105854656,"authorId":3586228965364851,"author":{"id":3586228965364851,"idStr":"3586228965364851","authorId":3586228965364851,"name":"yyhwin12345","avatar":"https://static.tigerbbs.com/f73f48f7dbf02904c9a179fb59cc138d","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.05","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983007338,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Lhi</span>","text":"<span class=\"s1\">Lhi</span>","html":"<span class=\"s1\">Lhi</span>"},{"id":104400667,"gmtCreate":1666105154016,"gmtModify":1666105157221,"authorId":3575200115109066,"author":{"id":3575200115109066,"idStr":"3575200115109066","authorId":3575200115109066,"name":"SiniS","avatar":"https://static.tigerbbs.com/6c54fb65b275549d9e3c4b80c5117022","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9983007338,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">👍🏻</span>","text":"<span class=\"s1\">👍🏻</span>","html":"<span class=\"s1\">👍🏻</span>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":283,"commentSize":16,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}